Hexima Limited

HXL

AU0000111932

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 05:41:16 07/05/2024 BST			5-day change	1st Jan Change
0.012 ^AUD	+20.00%		+9.09%	-33.33%

03-22	Hexima Secures R&D Tax Rebate for Fiscal Year 2023	MT
03-19	Hexima Changes Address	MT

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

November 29, 2023 at 09:07 am

Hexima Limited announced that Dr. Nicole van der Weerden has resigned as a director of the company effective 28 November 2023, as she pursues other endeavours.

Latest news about Hexima Limited

Hexima Secures R&D Tax Rebate for Fiscal Year 2023	03-22	MT
Hexima Changes Address	03-19	MT
Hexima Limited Announces Change of Address	03-19	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director	11-29	CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director	19/09/23	CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director	06/09/23	CI
Hexima Limited Announces Executive Changes	06/09/23	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director	11/05/23	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Hexima Limited Declares Voting Results	31/01/23	CI
Arovella Therapeutics Appoints COO	04/01/23	MT
Hexima Acting CEO to Step Down	22/12/22	MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited	22/12/22	CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office	14/12/22	MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund	13/12/22	CI
Hexima Limited Announces Board Changes	04/12/22	CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	30/11/22	CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	30/11/22	CI
Hexima Limited Announces Change of Address	12/09/22	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
Hexima Managing Director, CEO Steps Down	02/08/22	MT
Hexima Limited Announces Management Changes	02/08/22	CI
Hexima Limited Announces Phase II Results of Pezadeftide	10/07/22	CI

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Companyâs assets, including its intellectual property and other intangible assets, to be realized.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HEXIMA LIMITED	-33.33%	1.32M
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research

Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Latest news about Hexima Limited

Chart Hexima Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research